Design
Editorial
Answers are grounded in this paper and cite their sources.
The editorial highlights the growing necessity of oncocardiology to manage the cardiovascular toxicities associated with various cancer therapies in an expanding population of cancer survivors.
Advances in the field of oncology research and therapy have led to improved outcomes and survival in patients with cancer. Projections from the SEER (Surveillance, Epidemiology, and End Results) database have shown a decreasing cancer incidence, with increasing survival now and in the coming years.1 With increasing survivorship, the prevalence of cardiotoxicities has also increased.2 Therefore, primary and oncology providers are encountering uncharted territory in the management of cancer therapy-related toxicities in their oncology patients and survivors.2 It is the need to manage these complications that has led to the development and growth of the field of oncocardiology.2 3 This editorial seeks to briefly summarise important aspects of oncocardiology and emphasise the necessity in growing this field. The field of oncocardiology predominantly focuses on cardiotoxic effects of cancer therapy (chemotherapy, radiation therapy and/or targeted therapy). Cardiotoxicity related to cancer therapy not only involves the development of cardiomyopathy by way of reduction in left ventricular ejection fraction (LVEF) or signs and symptoms of heart failure (HF) but also includes other cardiac adverse effects of cancer therapy, including coronary artery disease (CAD), severe hypertension, arrhythmias, pericardial disease, among others.4 For instance, the most widely known cardiotoxicities are associated with anthracycline exposure (particularly doxorubicin) causing direct myocardial and endothelial cell injury leading to reduction in LVEF, cardiomyopathy and HF.3 5 Additionally, trastuzumab—a HER2/neu targeted agent (widely used in HER2-positive breast cancers)—is known to cause cardiac dysfunction linked to molecular pathways in cardiac myocytes and a propensity towards increased sympathetic tone.6 As such, monitoring of cardiac function while on these drugs has become standard practice.3 6 Similar to the aforementioned agents, there are additional classes of cancer therapies with associated cardiotoxicities including tyrosine kinase inhibitors that cause severe hypertension, thromboembolic events and cardiomyopathy; platinum-based agents that can cause CAD, endothelial dysfunction and metabolic syndrome with increased risk for cardiovascular events and 5-fluorouracil that can lead to coronary spasms and ventricular arrhythmias.3 6 Even newer targeted therapies such as vascular endothelial growth factor signalling pathway inhibitors, such as bevacizumab and monoclonal antibodies, carry a significant risk of severe hypertension and cardiomyopathy.3 6 Furthermore, radiation therapy causes myocyte fibrosis leading to restrictive cardiomyopathy, acute or subacute pericarditis, significant CAD and valvular abnormalities; in certain cases presenting during survivorship years.3
No takes yet. Share an insight, caveat, or question.
Bhatt et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: